Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.89 |
| ▸ | DPP4 | P27487 | 1/20 | 0.89 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.89 |
| ▸ | RELA | Q04206 | 1/20 | 0.89 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.88 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.79 |
| ▸ | MAPT | P10636 | 5/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.73 |
| ▸ | TP53 | P04637 | 2/20 | 0.73 |
| ▸ | ATM | Q13315 | 1/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.73 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL633183 | 1.00 | NFKB1 (0.89) | NFKB1DPP4NFKB2RELAABCG2 | |
| SCHEMBL25200484 | 1.00 | NFKB1 (0.89) | NFKB1DPP4NFKB2RELAABCG2 | |
| Flavokawain C SCHEMBL144230 | 0.94 | NFKB1 (1.00) | NFKB1DPP4NFKB2RELAABCG2 | |
| Flavokawain C SCHEMBL144231 | 0.94 | NFKB1 (1.00) | NFKB1DPP4NFKB2RELAABCG2 | |
| Flavokawain C SCHEMBL25201341 | 0.94 | NFKB1 (1.00) | NFKB1DPP4NFKB2RELAABCG2 | |
| Flavokawain C SCHEMBL30384247 | 0.94 | NFKB1 (1.00) | NFKB1DPP4NFKB2RELAABCG2 | |
| Flavokawain C SCHEMBL25206856 | 0.93 | NFKB1 (0.97) | NFKB1DPP4NFKB2RELAABCG2 | |
| SCHEMBL4834935 | 0.91 | TDP1 (0.83) | NFKB1DPP4NFKB2RELAABCG2 | |
| 4,2',4',6'-Tetramethoxychalcone SCHEMBL633892 | 0.91 | ABCG2 (0.94) | NFKB1DPP4NFKB2RELAABCG2 | |
| 4,2',4',6'-Tetramethoxychalcone SCHEMBL633215 | 0.91 | ABCG2 (0.94) | NFKB1DPP4NFKB2RELAABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2017132135-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-03 | — | — | WO | disclosed |
| EP-1888174-B1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | JOHNSON & JOHNSON CONSUMER (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| US-20060270614-A1 | Use of chalcones for the treatment of viral disorders | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | NFKB1 1115/4885DPP4 1159/4885NFKB2 1419/4885 |
| US-20060270614-A1 | Use of chalcones for the treatment of viral disorders | HAVCR2, HMGB3, EIF2AK2 | NFKB1 1144/4885DPP4 1783/4885NFKB2 1712/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | NFKB1 1669/4885DPP4 4226/4885NFKB2 1728/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | NFKB1 2437/4885DPP4 3670/4885NFKB2 2273/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | NFKB1 2437/4885DPP4 3670/4885NFKB2 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.